MRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system

Dipak V. Amrutkar, Kenneth B. Ploug, Anders Hay-Schmidt, Frank Porreca, Jes Olesen, Inger Jansen-Olesen

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Triptans, a family of 5-hydroxytryptamine (5-HT) 1B, 1D, and 1F receptor agonists, are used in the acute treatment of migraine attacks. The site of action and subtypes of the 5-HT 1 receptor that mediate the antimigraine effect have still to be identified. This study investigated the mRNA expression of these receptors and the role of 5-HT 1 receptor subtypes in controlling the release of calcitonin gene-related peptide (CGRP) in rat dura mater, trigeminal ganglion (TG), and trigeminal nucleus caudalis (TNC). The mRNA for each receptor subtype was quantified by quantitative real-time polymerase chain reaction. A high potassium concentration was used to release CGRP from dura mater, isolated TG, and TNC in vitro. The immunoreactive CGRP (iCGRP) release was measured by enzyme-linked immunoassay. The mRNA transcripts of the 3 5-HT 1 receptor subtypes were detected in the trigeminovascular system. Sumatriptan inhibited iCGRP release by 31% in dura mater, 44% in TG, and 56% in TNC. This effect was reversed by a 5-HT 1B/1D antagonist (GR127395). The 5-HT 1F agonist (LY-344864) was effective in the dura mater (26% iCGRP inhibition), and the 5-HT 1D agonist (PNU-142633) had a significant effect in the TNC (48%), whereas the 5-HT 1B agonist (CP-94253) was unable to reduce the iCGRP release in all tissues studied. We found that sumatriptan reduced the iCGRP release via activation of 5-HT 1D and 5-HT 1F receptor subtypes. The 5-HT 1F receptor agonist was effective only in peripheral terminals in dura mater, whereas the 5-HT 1D agonist had a preferential effect on central terminals in the TNC.

Original languageEnglish (US)
Pages (from-to)830-838
Number of pages9
JournalPain
Volume153
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Trigeminal Nuclei
Dura Mater
Calcitonin Gene-Related Peptide
Serotonin Receptor Agonists
Serotonin Receptors
Serotonin
Trigeminal Ganglion
Sumatriptan
Messenger RNA
Tryptamines
Receptors, Serotonin, 5-HT3
Migraine Disorders
Immunoenzyme Techniques
Real-Time Polymerase Chain Reaction
Potassium

Keywords

  • CGRP
  • Migraine

ASJC Scopus subject areas

  • Clinical Neurology
  • Anesthesiology and Pain Medicine
  • Neurology
  • Pharmacology

Cite this

MRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system. / Amrutkar, Dipak V.; Ploug, Kenneth B.; Hay-Schmidt, Anders; Porreca, Frank; Olesen, Jes; Jansen-Olesen, Inger.

In: Pain, Vol. 153, No. 4, 04.2012, p. 830-838.

Research output: Contribution to journalArticle

Amrutkar, Dipak V. ; Ploug, Kenneth B. ; Hay-Schmidt, Anders ; Porreca, Frank ; Olesen, Jes ; Jansen-Olesen, Inger. / MRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system. In: Pain. 2012 ; Vol. 153, No. 4. pp. 830-838.
@article{4a219e70fca746378380da6a47674b8e,
title = "MRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system",
abstract = "Triptans, a family of 5-hydroxytryptamine (5-HT) 1B, 1D, and 1F receptor agonists, are used in the acute treatment of migraine attacks. The site of action and subtypes of the 5-HT 1 receptor that mediate the antimigraine effect have still to be identified. This study investigated the mRNA expression of these receptors and the role of 5-HT 1 receptor subtypes in controlling the release of calcitonin gene-related peptide (CGRP) in rat dura mater, trigeminal ganglion (TG), and trigeminal nucleus caudalis (TNC). The mRNA for each receptor subtype was quantified by quantitative real-time polymerase chain reaction. A high potassium concentration was used to release CGRP from dura mater, isolated TG, and TNC in vitro. The immunoreactive CGRP (iCGRP) release was measured by enzyme-linked immunoassay. The mRNA transcripts of the 3 5-HT 1 receptor subtypes were detected in the trigeminovascular system. Sumatriptan inhibited iCGRP release by 31{\%} in dura mater, 44{\%} in TG, and 56{\%} in TNC. This effect was reversed by a 5-HT 1B/1D antagonist (GR127395). The 5-HT 1F agonist (LY-344864) was effective in the dura mater (26{\%} iCGRP inhibition), and the 5-HT 1D agonist (PNU-142633) had a significant effect in the TNC (48{\%}), whereas the 5-HT 1B agonist (CP-94253) was unable to reduce the iCGRP release in all tissues studied. We found that sumatriptan reduced the iCGRP release via activation of 5-HT 1D and 5-HT 1F receptor subtypes. The 5-HT 1F receptor agonist was effective only in peripheral terminals in dura mater, whereas the 5-HT 1D agonist had a preferential effect on central terminals in the TNC.",
keywords = "CGRP, Migraine",
author = "Amrutkar, {Dipak V.} and Ploug, {Kenneth B.} and Anders Hay-Schmidt and Frank Porreca and Jes Olesen and Inger Jansen-Olesen",
year = "2012",
month = "4",
doi = "10.1016/j.pain.2012.01.005",
language = "English (US)",
volume = "153",
pages = "830--838",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - MRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system

AU - Amrutkar, Dipak V.

AU - Ploug, Kenneth B.

AU - Hay-Schmidt, Anders

AU - Porreca, Frank

AU - Olesen, Jes

AU - Jansen-Olesen, Inger

PY - 2012/4

Y1 - 2012/4

N2 - Triptans, a family of 5-hydroxytryptamine (5-HT) 1B, 1D, and 1F receptor agonists, are used in the acute treatment of migraine attacks. The site of action and subtypes of the 5-HT 1 receptor that mediate the antimigraine effect have still to be identified. This study investigated the mRNA expression of these receptors and the role of 5-HT 1 receptor subtypes in controlling the release of calcitonin gene-related peptide (CGRP) in rat dura mater, trigeminal ganglion (TG), and trigeminal nucleus caudalis (TNC). The mRNA for each receptor subtype was quantified by quantitative real-time polymerase chain reaction. A high potassium concentration was used to release CGRP from dura mater, isolated TG, and TNC in vitro. The immunoreactive CGRP (iCGRP) release was measured by enzyme-linked immunoassay. The mRNA transcripts of the 3 5-HT 1 receptor subtypes were detected in the trigeminovascular system. Sumatriptan inhibited iCGRP release by 31% in dura mater, 44% in TG, and 56% in TNC. This effect was reversed by a 5-HT 1B/1D antagonist (GR127395). The 5-HT 1F agonist (LY-344864) was effective in the dura mater (26% iCGRP inhibition), and the 5-HT 1D agonist (PNU-142633) had a significant effect in the TNC (48%), whereas the 5-HT 1B agonist (CP-94253) was unable to reduce the iCGRP release in all tissues studied. We found that sumatriptan reduced the iCGRP release via activation of 5-HT 1D and 5-HT 1F receptor subtypes. The 5-HT 1F receptor agonist was effective only in peripheral terminals in dura mater, whereas the 5-HT 1D agonist had a preferential effect on central terminals in the TNC.

AB - Triptans, a family of 5-hydroxytryptamine (5-HT) 1B, 1D, and 1F receptor agonists, are used in the acute treatment of migraine attacks. The site of action and subtypes of the 5-HT 1 receptor that mediate the antimigraine effect have still to be identified. This study investigated the mRNA expression of these receptors and the role of 5-HT 1 receptor subtypes in controlling the release of calcitonin gene-related peptide (CGRP) in rat dura mater, trigeminal ganglion (TG), and trigeminal nucleus caudalis (TNC). The mRNA for each receptor subtype was quantified by quantitative real-time polymerase chain reaction. A high potassium concentration was used to release CGRP from dura mater, isolated TG, and TNC in vitro. The immunoreactive CGRP (iCGRP) release was measured by enzyme-linked immunoassay. The mRNA transcripts of the 3 5-HT 1 receptor subtypes were detected in the trigeminovascular system. Sumatriptan inhibited iCGRP release by 31% in dura mater, 44% in TG, and 56% in TNC. This effect was reversed by a 5-HT 1B/1D antagonist (GR127395). The 5-HT 1F agonist (LY-344864) was effective in the dura mater (26% iCGRP inhibition), and the 5-HT 1D agonist (PNU-142633) had a significant effect in the TNC (48%), whereas the 5-HT 1B agonist (CP-94253) was unable to reduce the iCGRP release in all tissues studied. We found that sumatriptan reduced the iCGRP release via activation of 5-HT 1D and 5-HT 1F receptor subtypes. The 5-HT 1F receptor agonist was effective only in peripheral terminals in dura mater, whereas the 5-HT 1D agonist had a preferential effect on central terminals in the TNC.

KW - CGRP

KW - Migraine

UR - http://www.scopus.com/inward/record.url?scp=84858708976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858708976&partnerID=8YFLogxK

U2 - 10.1016/j.pain.2012.01.005

DO - 10.1016/j.pain.2012.01.005

M3 - Article

C2 - 22305629

AN - SCOPUS:84858708976

VL - 153

SP - 830

EP - 838

JO - Pain

JF - Pain

SN - 0304-3959

IS - 4

ER -